• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

总体拷贝数变异作为成人星形细胞瘤亚型的预后因素。

Total copy number variation as a prognostic factor in adult astrocytoma subtypes.

机构信息

Department of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.

Eugene McDermott Center for Human Growth & Development, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

出版信息

Acta Neuropathol Commun. 2019 Jun 10;7(1):92. doi: 10.1186/s40478-019-0746-y.

DOI:10.1186/s40478-019-0746-y
PMID:31177992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6556960/
Abstract

Since the discovery that IDH1/2 mutations confer a significantly better prognosis in astrocytomas, much work has been done to identify other molecular signatures to help further stratify lower-grade astrocytomas and glioblastomas, with the goal of accurately predicting clinical outcome and identifying potentially targetable mutations. In the present study, we subclassify 135 astrocytomas (67 IDH-wildtype and 68 IDH-mutant) from The Cancer Genome Atlas dataset (TCGA) on the basis of grade, IDH-status, and the previously established prognostic factors, CDK4 amplification and CDKN2A/B deletion, within the IDH-mutant groups. We analyzed these groups for total copy number variation (CNV), total mutation burden, chromothripsis, specific mutations, and amplifications/deletions of specific genes/chromosomal regions. Herein, we demonstrate that across all of these tumor groups, total CNV level is a relatively consistent prognostic factor. We also identified a trend towards increased levels of chromothripsis in tumors with lower progression-free survival (PFS) and overall survival (OS) intervals. While no significant differences were identified in overall mutation load, we did identify a significantly higher number of cases with mutations in genes with functions related to maintaining genomic stability in groups with higher mean CNV and worse PFS and OS intervals, particularly in the IDH-mutant groups. Our data further support the case for total CNV level as a potential prognostic factor in astrocytomas, and suggest mutations in genes responsible for overall genomic instability as a possible underlying mechanism for some astrocytomas with poor clinical outcome.

摘要

自发现 IDH1/2 突变可显著改善星形细胞瘤的预后以来,人们做了大量工作来确定其他分子特征,以帮助进一步对低级别星形细胞瘤和胶质母细胞瘤进行分层,目的是准确预测临床结果并确定潜在的可靶向突变。在本研究中,我们根据等级、IDH 状态和先前建立的预后因素(IDH 突变组中的 CDK4 扩增和 CDKN2A/B 缺失),对来自癌症基因组图谱数据集(TCGA)的 135 例星形细胞瘤(67 例 IDH 野生型和 68 例 IDH 突变型)进行亚分类。我们分析了这些组的总拷贝数变异(CNV)、总突变负担、染色体重排、特定突变以及特定基因/染色体区域的扩增/缺失。在此,我们证明在所有这些肿瘤组中,总 CNV 水平是一个相对一致的预后因素。我们还发现,在无进展生存期(PFS)和总生存期(OS)间隔较短的肿瘤中,染色体重排水平有升高的趋势。虽然总突变负荷没有显著差异,但我们确实发现,在 CNV 水平较高且 PFS 和 OS 间隔较差的组中,与维持基因组稳定性相关的功能的基因突变数量明显更高,尤其是在 IDH 突变组中。我们的数据进一步支持将总 CNV 水平作为星形细胞瘤潜在预后因素的观点,并表明基因组不稳定性相关基因的突变可能是某些临床预后不良的星形细胞瘤的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/8ea9a69566c2/40478_2019_746_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/f6a006b97913/40478_2019_746_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/566a325a088b/40478_2019_746_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/5836d6c466c4/40478_2019_746_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/ca35ab5c78c5/40478_2019_746_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/53dd196d7830/40478_2019_746_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/34736e224942/40478_2019_746_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/310c5c366113/40478_2019_746_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/8ea9a69566c2/40478_2019_746_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/f6a006b97913/40478_2019_746_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/566a325a088b/40478_2019_746_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/5836d6c466c4/40478_2019_746_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/ca35ab5c78c5/40478_2019_746_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/53dd196d7830/40478_2019_746_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/34736e224942/40478_2019_746_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/310c5c366113/40478_2019_746_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4955/6556960/8ea9a69566c2/40478_2019_746_Fig8_HTML.jpg

相似文献

1
Total copy number variation as a prognostic factor in adult astrocytoma subtypes.总体拷贝数变异作为成人星形细胞瘤亚型的预后因素。
Acta Neuropathol Commun. 2019 Jun 10;7(1):92. doi: 10.1186/s40478-019-0746-y.
2
Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.分子特征与染色体不稳定性与 IDH 突变型和 IDH 野生型星形细胞瘤的拷贝数变异模式和患者预后相关。
J Neuropathol Exp Neurol. 2021 Mar 22;80(4):354-365. doi: 10.1093/jnen/nlab008.
3
Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.确定成人异柠檬酸脱氢酶(IDH)突变的II/III级星形细胞瘤中总拷贝数变异的预后阈值。
Acta Neuropathol Commun. 2019 Jul 26;7(1):121. doi: 10.1186/s40478-019-0778-3.
4
MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.磁共振成像表型与 IDH 突变型胶质瘤全基因组拷贝数丰度的范围相关。
Neuroradiology. 2019 Sep;61(9):1023-1031. doi: 10.1007/s00234-019-02219-8. Epub 2019 May 27.
5
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.IDH 突变型低级别(WHO 分级 II/III)星形细胞瘤可通过 CDKN2A、CDK4 和 PDGFRA 拷贝数改变进行风险分层。
Brain Pathol. 2020 May;30(3):541-553. doi: 10.1111/bpa.12801. Epub 2019 Dec 3.
6
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.错配修复蛋白 PMS2 和 MLH1 可进一步细化 IDH 突变型低级别星形细胞瘤的分子分层。
Clin Neurol Neurosurg. 2021 Sep;208:106882. doi: 10.1016/j.clineuro.2021.106882. Epub 2021 Aug 10.
7
The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.异柠檬酸脱氢酶突变在接受同源治疗的间变性星形细胞瘤和胶质母细胞瘤患者中的预后作用。
Acta Neuropathol Commun. 2019 Oct 17;7(1):156. doi: 10.1186/s40478-019-0817-0.
8
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.异柠檬酸脱氢酶(IDH)突变型星形细胞瘤亚组中快速进展为胶质母细胞瘤:全基因组分析
J Neurooncol. 2017 May;133(1):183-192. doi: 10.1007/s11060-017-2431-y. Epub 2017 Apr 18.
9
T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.T2-FLAIR 错配信号预测 IDH 突变星形细胞瘤中的 DNA 甲基化亚类和 CDKN2A/B 状态。
Clin Cancer Res. 2024 Aug 15;30(16):3512-3519. doi: 10.1158/1078-0432.CCR-24-0311.
10
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.新型改良的 IDH 突变型星形细胞瘤分级系统。
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

引用本文的文献

1
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.表皮生长因子受体(EGFR)改变是异柠檬酸脱氢酶(IDH)突变型星形细胞瘤的不良预后因素。
Acta Neuropathol. 2025 Aug 19;150(1):20. doi: 10.1007/s00401-025-02928-w.
2
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival.异柠檬酸脱氢酶(IDH)突变型星形细胞瘤的纵向分析揭示了与较差生存率相关的获得性RAS-丝裂原活化蛋白激酶(MAPK)通路突变。
Neurooncol Adv. 2025 Jan 29;7(1):vdaf024. doi: 10.1093/noajnl/vdaf024. eCollection 2025 Jan-Dec.
3
Therapy enhancing chromosome instability may be advantageous for gliomas.

本文引用的文献

1
Astrocytoma progression scoring system based on the WHO 2016 criteria.基于 WHO 2016 标准的星形细胞瘤进展评分系统。
Sci Rep. 2019 Jan 14;9(1):96. doi: 10.1038/s41598-018-36471-4.
2
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.CBTRUS统计报告:2011 - 2015年美国原发性脑肿瘤及其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
3
Maftools: efficient and comprehensive analysis of somatic variants in cancer.
增强染色体不稳定性的疗法可能对神经胶质瘤有利。
NAR Cancer. 2025 Feb 13;7(1):zcaf003. doi: 10.1093/narcan/zcaf003. eCollection 2025 Mar.
4
IDH-mutant gliomas in children and adolescents - from biology to clinical trials.儿童和青少年异柠檬酸脱氢酶(IDH)突变型神经胶质瘤——从生物学特性到临床试验
Front Oncol. 2025 Jan 6;14:1515538. doi: 10.3389/fonc.2024.1515538. eCollection 2024.
5
The molecular history of IDH-mutant astrocytomas without adjuvant treatment.未接受辅助治疗的异柠檬酸脱氢酶(IDH)突变型星形细胞瘤的分子史。
Brain Pathol. 2025 Mar;35(2):e13300. doi: 10.1111/bpa.13300. Epub 2024 Oct 30.
6
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.遗传和表观遗传不稳定性是 IDH 突变型星形细胞瘤进展和侵袭性行为的潜在驱动因素。
Acta Neuropathol. 2024 Jul 16;148(1):5. doi: 10.1007/s00401-024-02761-7.
7
T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.T2-FLAIR 错配信号预测 IDH 突变星形细胞瘤中的 DNA 甲基化亚类和 CDKN2A/B 状态。
Clin Cancer Res. 2024 Aug 15;30(16):3512-3519. doi: 10.1158/1078-0432.CCR-24-0311.
8
Chromothripsis is rare in IDH-mutant gliomas compared to IDH-wild-type glioblastomas whereas whole-genome duplication is equally frequent in both tumor types.与异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤相比,染色体碎裂在IDH突变型神经胶质瘤中较为罕见,而全基因组复制在这两种肿瘤类型中出现的频率相当。
Neurooncol Adv. 2024 Apr 18;6(1):vdae059. doi: 10.1093/noajnl/vdae059. eCollection 2024 Jan-Dec.
9
Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.儿科脑星形细胞瘤的遗传学和表观遗传学临床靶点的新见解。
Clin Transl Med. 2024 Feb;14(2):e1560. doi: 10.1002/ctm2.1560.
10
Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification.基于 DNA 甲基化分类的 IDH 突变型星形细胞瘤预后的细化。
Brain Pathol. 2024 Sep;34(5):e13233. doi: 10.1111/bpa.13233. Epub 2024 Jan 2.
Maftools:癌症体细胞变异的高效全面分析。
Genome Res. 2018 Nov;28(11):1747-1756. doi: 10.1101/gr.239244.118. Epub 2018 Oct 19.
4
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".cIMPACT-NOW更新3:“弥漫性星形细胞胶质瘤,IDH野生型,具有胶质母细胞瘤分子特征,WHO四级”的推荐诊断标准。
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
5
Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.脑肿瘤中 EGFR 扩增、染色体 7 联合增益和染色体 10 缺失以及 TERT 启动子突变的分布及其对 IDHwt 星形细胞瘤重新分类为胶质母细胞瘤的潜在影响。
Acta Neuropathol. 2018 Nov;136(5):793-803. doi: 10.1007/s00401-018-1905-0. Epub 2018 Sep 5.
6
Satisfying your neuro-oncologist: a fast approach to routine molecular glioma diagnostics.令神经肿瘤学家满意:一种快速进行常规分子胶质瘤诊断的方法。
Neuro Oncol. 2018 Nov 12;20(12):1682-1683. doi: 10.1093/neuonc/noy128.
7
Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.快速进展型 IDH 突变星形细胞瘤的遗传和表观遗传特征。
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):542-548. doi: 10.1093/jnen/nly026.
8
Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.将分子病理学的进展纳入脑肿瘤诊断中。
Adv Anat Pathol. 2018 May;25(3):143-171. doi: 10.1097/PAP.0000000000000186.
9
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.弥漫性星形细胞瘤,IDH 野生型:一个正在溶解的诊断。
J Neuropathol Exp Neurol. 2018 Jun 1;77(6):422-425. doi: 10.1093/jnen/nly012.
10
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.CBTRUS统计报告:2010 - 2014年在美国诊断出的原发性脑和其他中枢神经系统肿瘤
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88. doi: 10.1093/neuonc/nox158.